Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lenvatinib

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

- PMLiVE

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer trial

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

Takeda announces EC approval for Adcetris combination in Hodgkin lymphoma

The ADC has been approved alongside doxorubicin, vinblastine and dacarbazine

- PMLiVE

Pfizer’s Litfulo approved by EC for adults and adolescents with severe alopecia areata

The autoimmune disease affects approximately 147 million people globally

EU flag

EC approves Otsuka and Astex’s Inaqovi for acute myeloid leukaemia

Inaqovi is the first oral hypomethylating agent approved for this patient population

Biomarin

BioMarin announces first patient dosed with haemophilia A gene therapy in Europe

The therapy was granted conditional marketing authorisation by the EC in August 2022

- PMLiVE

Merck receives EC approval for Keytruda combination in gastric cancer

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Roche’s spinal muscular atrophy therapy Evrysdi approved by EC for newborns

The neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Pfizer’s RSV vaccine granted EC approval to protect infants and older adults

The decision allows Abrysvo to be given to those who are 24 to 36 weeks into their pregnancy

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

- PMLiVE

Janssen’s Tecvayli approved by EC for reduced dosing frequency in multiple myeloma

Tecvayli was the first BCMA-targeting bispecific antibody to be approved in Europe

- PMLiVE

Merck shares positive late-stage results for Welireg in advanced kidney cancer

Renal cell carcinoma accounts for approximately 90% of kidney cancer diagnoses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links